[S-28] シンポジウム28 Novel therapeutic strategies against ischemic stroke from the perspective of neuro-glial-vascular unit

[S-28-3] The Effects of TrkB agonist for changing A1 to A2 astrocyte under prolonged cerebral hypoperfusion

^○宮元 伸和¹, 眞上 俊亮², 平 健一郎¹, 稲葉 俊東¹, 上野 祐司¹, 服部 信孝¹ (1.順天堂大学医学部附属順天堂医院 脳神経内科, 2.順天堂大学医学部附属順天堂医院 脳神経外科)

Dr. Nobukazu Miyamoto received his MD degree from Juntendo University in 2001. He received his PhD from Juntendo University in 2009 and was appointed Assistant Professor of Neurology at Juntendo University in the same year. In 2011-2013, he joined Neuroprotection Research Laboratory at Massachusetts General Hospital/Harvard Medical School as Research Fellow. He moved to Juntendo Urayasu hospital in 2013-2016, as Assistant Professor. Since he moved to the Neurology at Juntendo University (Prof Hattori N.) in 2017 as Associate Professor, his research interests have focused on oligodendrogenesis and cell-cell interaction between oligodendrocyte and other cells under chronic cerebral hypoperfusion in white matter, and neuroprotection of acute cerebral ischemia in basic science, and neurological deterioration of ischemic stroke in clinical research.